Journal
VIRUSES-BASEL
Volume 15, Issue 5, Pages -Publisher
MDPI
DOI: 10.3390/v15051128
Keywords
COVID-19; drug repurposing; methotrexate; EXSCALATE; virtual screening; molecular docking; anti-viral activity; SARS-CoV-2; viral entry; nsp13
Categories
Ask authors/readers for more resources
During the COVID-19 pandemic, drug repurposing was an effective strategy in quickly addressing medical emergencies. The anti-viral activity of DHFR inhibitors, including methotrexate, against SARS-CoV-2 was evaluated using cell lines. Results showed that these inhibitors not only had intrinsic anti-metabolic activity but also specific anti-viral functions, making them potential candidates for managing SARS-CoV-2 infection.
During the COVID-19 pandemic, drug repurposing represented an effective strategy to obtain quick answers to medical emergencies. Based on previous data on methotrexate (MTX), we evaluated the anti-viral activity of several DHFR inhibitors in two cell lines. We observed that this class of compounds showed a significant influence on the virus-induced cytopathic effect (CPE) partly attributed to the intrinsic anti-metabolic activity of these drugs, but also to a specific anti-viral function. To elucidate the molecular mechanisms, we took advantage of our EXSCALATE platform for in-silico molecular modelling and further validated the influence of these inhibitors on nsp13 and viral entry. Interestingly, pralatrexate and trimetrexate showed superior effects in counteracting the viral infection compared to other DHFR inhibitors. Our results indicate that their higher activity is due to their polypharmacological and pleiotropic profile. These compounds can thus potentially give a clinical advantage in the management of SARS-CoV-2 infection in patients already treated with this class of drugs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available